United States  

Coronavirus Vaccine Trial by Moderna Shows Promising Early Results

NYTimes.com Monday, 18 May 2020
The company said its preliminary test in 8 healthy volunteers was safe. It is on an accelerated timetable to begin a larger human trial soon.
0
shares
ShareTweetSavePostSend
 
Video Credit: WCVB - Published
News video: Moderna announces 'positive' early results in coronavirus vaccine trial

Moderna announces 'positive' early results in coronavirus vaccine trial 01:06

The vaccine candidate "has the potential to prevent COVID-19 disease," said Dr. Tal Zaks.

You Might Like


Related videos from verified sources

Coronavirus Vaccine From China Is Safe In Early Trial [Video]

Coronavirus Vaccine From China Is Safe In Early Trial

A coronavirus vaccine developed by CanSino Biologics Inc appears to be safe. It induced a rapid immune response in its first human trial, Reuters reports. This vaccine did not cause any serious adverse..

Credit: Wochit Business     Duration: 00:39Published
Dr. Fauci Is 'Cautiously Optimistic' About Possibility Of COVID-19 Vaccine [Video]

Dr. Fauci Is 'Cautiously Optimistic' About Possibility Of COVID-19 Vaccine

Researchers working on a vaccine for the novel coronavirus have announced promising results in a very small drug trial. Biotech company Moderna said the first phase of trials for a COVID-19 vaccine..

Credit: Wochit     Duration: 00:32Published
AstraZeneca to make billion COVID vaccine doses if tests succeed [Video]

AstraZeneca to make billion COVID vaccine doses if tests succeed

AstraZeneca expects to be able to deliver a billion doses of a possible COVID-19 vaccine this year and next if tests are successful, adding on Thursday it should shortly get results of an early stage..

Credit: Reuters Studio     Duration: 01:20Published

Related news from verified sources

Moderna Coronavirus Vaccine Trial Shows Promising Early Results

The first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the infection, the manufacturer,...
Seattle Times

Moderna skyrockets 29% after its early trial for a coronavirus vaccine produced antibodies in all 45 patients (MRNA)

Moderna skyrockets 29% after its early trial for a coronavirus vaccine produced antibodies in all 45 patients (MRNA)
** · *Moderna announced on Monday that its early trial for its coronavirus vaccine produced antibodies in all patients. * · *Shares of the company surged...
Business Insider Also reported by •Proactive InvestorsSeattle TimesSeattlePI.comNewsmaxMotley Fool

S&P Stumbles as Moderna Sinks on Report Questioning Trial Results

The S&P 500 closed lower on Tuesday, as investors focused on a report questioning Moderna's recent coronavirus vaccine early-stage trial results, wiping out...
Newsmax


Tweets about this